SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

United States Commodity Funds LLC - United States Oil Fund

United States Oil Fund

USO is trending as mounting geopolitical tensions with Iran, coupled with a significant US military buildup in the Middle East, ignite intense community speculation about potential oil supply disruptions and a "war premium" for crude.

Moonlake Immunotherapeutics operates as a clinical-stage biotechnology company. It offers tri-specific Nanobody, Sonelokimab to address significant unmet needs in inflammatory skin and joint diseases. The company was founded by Kristian Reich, Jorge Santos da Silva, and Arnout Ploos van Amstel in 2021 and is headquartered in Zug, Switzerland.

MoonLake Immunotherapeutics - Ordinary Shares - Class A

MoonLake Immunotherapeutics

MoonLake Immunotherapeutics is trending after announcing positive Phase 2 S-OLARIS trial results for sonelokimab in axial spondyloarthritis, showcasing "disease modifying" potential and "best-in-class" efficacy. The community anticipates a significant re-valuation and potential short squeeze, fueled by strong financial positioning and upcoming Investor Day presentations.

Tidal Trust III - Fundstrat Granny Shots US Large Cap ETF

Fundstrat Granny Shots US Large Cap ETF

Fundstrat Granny Shots US Large Cap ETF is trending due to its rapid growth, surpassing $3 billion in assets under management and becoming one of the fastest-growing active ETFs. The community is actively discussing Tom Lee's market insights and the fund's strong performance, often weighing it against its notable expense ratio.

SSgA Active Trust - State Street Utilities Select Sector SPDR ETF

Utilities Select Sector SPDR Fund

The Utilities Select Sector SPDR Fund (XLU) is trending due to its dual appeal as a traditional defensive safe haven and a significant beneficiary of the escalating electricity demands from AI data centers. The community is actively discussing its robust performance and strategic positioning amidst broader market shifts.

Gemini Space Station, Inc. is a holding company, which offers a mobile and web based crypto asset exchange platform, proprietary wallet infrastructure and custody solutions, over-the-counter trading solutions tailored to institutions and professionals, a digital art auction platform, a proprietary United States dollar backed stablecoin, and a credit card product that offers crypto asset rewards on customer purchases. The company was founded by Tyler Winklevoss and Cameron Winklevoss in 2014 and is headquartered in New York, NY.

Gemini Space Station Inc. - Ordinary Shares- Class A

Gemini Space Station

Gemini Space Station is trending as it grapples with the recent departure of its COO, CFO, and CLO, alongside weak preliminary guidance and a strategic exit from international markets. This corporate overhaul fuels community concern and frustration regarding the company's stability and prior IPO performance, despite some bullish outlooks on its prediction market and crypto potential.

Super Group (SGHC) Ltd. is a global digital gaming company, which engages in the global online sports betting and gaming businesses, Betway, a premier online sports betting brand, and Spin, a multi-brand online casino offering. It operates through the following segments: Betway, Spin, and Other. The Betway segment focuses on the ingle brand online sportsbook and online casino focused business with a global footprint and strategic partnerships. The Spin segment relates to the multi-brand online casino focused business with established market leadership in high-growth markets. The company was founded in July 2020 and is headquartered in St. Peter Port, the United Kingdom.

Super Group (SGHC) Limited

Super Group (SGHC) is trending amid discussions of a potential short squeeze, fueled by recent strong financial results that include Q3 earnings beats, raised guidance, and a special dividend. The community highlights its debt-free, profitable status and global focus, particularly in Africa and Europe, positioning it as an undervalued player in the iGaming sector despite broader market volatility.

First Majestic Silver Corp. engages in the production, development, exploration and acquisition of mineral properties. It owns and operates producing mines in México including the La Encantada Silver Mine, La Parrilla Silver Mine, San Martin Silver Mine, La Guitarra Silver Mine, Del Toro Silver Mine, Santa Elena Silver & Gold Mine, and San Dimas Silver & Gold Mine. The company was founded by Keith Neumeyer on September 26, 1979 and is headquartered in Vancouver, Canada.

First Majestic Silver Corporation

First Majestic Silver is trending following its robust Q4 and full-year 2025 earnings report, which highlighted record revenue and strong production fueled by elevated silver prices. The community is highly bullish, emphasizing the company's unique advantage of owning its own mint, its strong correlation to the metal's rising value, and its potential for significant upside amidst ongoing discussions of silver scarcity and market dynamics.

The Render Network is a leading decentralized GPU compute platform for applications ranging from 3D rendering to machine learning and generative AI.  The network connects node operators looking to monetize their idle GPU compute power with artists and developers looking to scale intensive 3D rendering work and machine learning applications in the cloud. Through a decentralized peer-to-peer network, the Render Network achieves unprecedented levels of scale, speed, and economic efficiency. Facilitated by the Render Network Foundation, the ecosystem empowers artists and developers to build services and applications for the emerging digital economy.

Render Token (SOL)

Render Token is generating significant buzz as a key player in the decentralized AI compute and DePIN sectors, driven by surging GPU demand and news of substantial funding. The community is actively discussing its growth potential, viewing its enhanced network efficiency and utility as catalysts for long-term appreciation.

U.S. Gold Corp. engages in the exploration of gold properties. It has properties in CK Gold Project, Wyoming, Challis Gold Project, Idaho, and Keystone, Nevada. The company was founded in 1967 and is headquartered in Elko, NV.

U.S. Gold Corp

U.S. Gold Corp. is actively discussed for its upcoming Russell index inclusion, anticipated to spark institutional buying due to a low float, and its awaited CK Gold Project Feasibility Study, all against a backdrop of rising gold and copper prices. Investors are debating its significant undervaluation and potential for an acquisition, while some express skepticism regarding heavy bot-driven promotion.

Direxion Shares ETF Trust - Direxion Daily South Korea Bull 3X Shares

Direxion Daily South Korea Bull 3X Shares

Direxion Daily South Korea Bull 3X Shares ($KORU) is attracting significant attention as investors actively discuss its substantial rally, largely propelled by the ongoing semiconductor boom and the strong performance of South Korean tech giants like Samsung and SK Hynix, though some question if the upward trend is stretched.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Immunic (IMUX) Projected to Post Quarterly Earnings on Thursday

Immunic (NASDAQ:IMUX) will be releasing its Q4 2025 earnings before the market opens on Thursday, February 26. (View Earnings Report at...

Immunic Announces Closing of Oversubscribed Private Placement Financing

Immunic Announces Closing of Oversubscribed Private Placement Financing Immunic Announces Closing of Oversubscribed Private Placement Financing PR Newswire NEW YORK, Feb. 17, 2026 Upfront Proceeds of...

Biotech Breakout: This Microcap Locks In Up to $400 Million to Fuel Late-Stage Push

In biotechnology, few milestones carry more weight than securing the capital required to cross the finish line. As clinical-stage companies approach pivotal trials and potential commercialization, access to substantial funding can dramatically reshape both timelines and investor perception.Shares of Immunic, Inc. (Nasdaq: IMUX) are climbing Friday morning after the late-stage biotechnology company announced an oversubscribed private placement of up to $400 million, priced at the market under Nasdaq rules. The financing includes $200 million in upfront gross proceeds, with the potential for ...

D. Boral Capital Lowers Immunic (NASDAQ:IMUX) Price Target to $4.00

D. Boral Capital cut their price target on shares of Immunic from $8.00 to $4.00 and set a "buy" rating for the company in a research note on Friday...

<ul class="summary-bullets"><li>Immunic plans to use the money raised to support its clinical studies, day-to-day operations, and other general business needs.</li><li>The company said that it&nbsp;is preparing to shift from a development-focused biotech into a commercial-stage company.</li><li>Immunic looks to prioritize its Phase 3 ENSURE studies evaluating vidofludimus calcium in relapsing multiple sclerosis, with top-line results anticipated by year-end 2026.</li></ul>Immunic Inc. (IMUX) announced on Friday that it has secured a private placement that could generate up to $400 million in gross proceeds, providing funding to advance its multiple sclerosis programs and support future product launches.The financing, led by existing investor BVF Partners and including several institutional backers, includes $200 million in upfront proceeds and the potential for an additional $200 million if warrants are exercised.&nbsp;The transaction is expected to close around February 17, pending customary conditions.<h2 class="st-heading-2">Financing To Advance Clinical Studies</h2>Immunic plans to use the money raised to support its clinical studies, day-to-day operations, and other general business needs. Together with its existing cash and investments, the funds are expected to cover operating and capital costs through the end of 2027.The company said that it&nbsp;is preparing to shift from a development-focused biotech into a commercial-stage company.Following the announcement,&nbsp;<a href="https://stocktwits.com/symbol/IMUX">Immunic stock</a> traded over 33% higher in Friday’s premarket.&nbsp;On Stocktwits, retail sentiment around the stock remained in ‘extremely bullish’ territory amid ‘extremely high’ message volume levels.&nbsp;<h2 class="st-heading-2">Multiple Sclerosis Programs Take Priority&nbsp;</h2>Immunic plans complete its Phase 3 ENSURE studies evaluating vidofludimus calcium in relapsing multiple sclerosis, with top-line results anticipated by year-end 2026. The company aims to file a New Drug Application in mid-2027 and, if approved, launch in 2028. It also intends to initiate a Phase 3 program in primary progressive multiple sclerosis later this year, a trial projected to run up to four years.<blockquote>“The proceeds from the initial closing are expected to provide sufficient runway through submission of an NDA in the United States in mid-2027 and to start preparations for the potential launch of vidofludimus calcium in RMS, as well as initiation of a phase 3 clinical program in PPMS.”-Daniel Vitt, CEO, Immunic</blockquote>Vitt will begin a search for a CEO to lead the next phase of growth. Vitt plans to transition into a senior strategic role while remaining on the board.IMUX stock has declined by 9% in the last 12 months.&nbsp;Also See:&nbsp;<a href="https://stocktwits.com/news-articles/markets/equity/aap-stock-surges-pre-market-what-s-fueling-the-rally/cZR5s0pR4sw">AAP Stock Surges 9% Pre-Market – What’s Fueling the Rally?</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

Why Did IMUX Stock Surge 33% Pre-Market Today? 

Immunic announced a private placement of up to $400 million to support its clinical studies and other operational needs.  

Equity

Immunic Announces Oversubscribed Private Placement of up to USD 400 Million to Accelerate Transformation into Commercial-Stage Company

Immunic Announces Oversubscribed Private Placement of up to USD 400 Million to Accelerate Transformation into Commercial-Stage Company Immunic Announces Oversubscribed Private Placement of up to USD...

HC Wainwright Reaffirms "Buy" Rating for Immunic (NASDAQ:IMUX)

HC Wainwright restated a "buy" rating and issued a $8.00 target price on shares of Immunic in a research report on Monday...

Brookline Cap M Predicts Immunic FY2025 Earnings

Immunic, Inc. (NASDAQ:IMUX - Free Report) - Brookline Cap M issued their FY2025 EPS estimates for shares of Immunic in a research note issued to investors on Tuesday, February 3rd. Brookline Cap M...

Immunic (NASDAQ:IMUX) Upgraded at Brookline Cap M

Brookline Cap M raised shares of Immunic to a "strong-buy" rating in a research note on Tuesday...

Immunic, Inc. is a clinical-stage biopharmaceutical company, which develops a pipeline of selective oral immunology therapies aimed at treating chronic inflammatory and autoimmune diseases. It focuses on multiple sclerosis, celiac disease and other neurologic and gastrointestinal disorders. The firm's products include IMU-838, IMU-856, and IMU-381. The company was founded in 2016 and is headquartered in New York, NY.

IMUX
Immunic Inc

Feed

News

Sentiment

Earnings

Fundamentals

Info

Poll

Latest IMUX News

IMUXImmunic Inc